Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

J&J says veteran Duato to replace Gorsky as chief executive

Stock Markets Aug 19, 2021 10:35PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: Johnson & Johnson Vice President and Worldwide Chairman Pharmaceuticals Joaquin Duato attends a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

By Carl O'Donnell and Manojna Maddipatla

(Reuters) -Johnson & Johnson on Thursday appointed Joaquin Duato as chief executive officer to replace veteran Alex Gorsky to steer the healthcare conglomerate through the remainder of the coronavirus pandemic.

Duato, the current vice chairman of the executive committee, will take the reins and a seat on the board from Jan. 3. Gorsky, who was at the helm for nine years, will become executive chairman.

The transition will put the world's largest drugmaker by market value in the hands of a company veteran who took a leading role in J&J (NYSE:JNJ)'s COVID-19 response and helped shape its pharmaceutical business strategy.

Gorsky said in a statement it was the right time to make the switch for both the company and him personally as he focuses more on family due to "family health reasons."

Gorsky oversaw massive growth during his tenure, establishing J&J as a major player in the rare diseases market and leading its development of the first single shot COVID-19 vaccine.

But he was also at the helm during some of the biggest crises in the company's history, including allegations its Baby Powder contained cancer-causing asbestos and litigation claiming it contributed to the U.S. opioid epidemic.

The "surprise and unexpected" leadership change comes at a challenging time for J&J, but the transition is likely to be smooth given that Duato is a well-known executive with a successful track record, CFRA Research analyst Sel Hardy said in an email.

Duato has held a variety of roles during his more than 30 years at J&J, most recently overseeing its pharmaceutical and consumer health businesses, which have a combined $60 billion in sales.

He helped establish a focus on the company's fastest growing therapeutic areas and helped lead the integration of data science and computer automation into J&J's research and operations.

During the pandemic, Duato led global initiatives "to safeguard the health of employees and ensure business and supply chain continuity," Gorsky said. Duato was also the chairman of the trade group Pharmaceutical Research and Manufacturers of America.

J&J's market capitalization rose from nearly $180 billion to more than $470 billion under Gorsky's tenure, while its its share price increased by more than 170%.

The company's cancer drug business grew from $2 billion in sales in 2011 to over $12 billion in 2020 thanks in large part to blockbuster blood cancer treatments Darzalex and Imbruvica.

The move into medicines for rare diseases was boosted by its $30 billion acquisition of Actelion, the largest in its history. The vaccines division made significant breakthroughs beyond its COVID-19 shot, including innoculations against Ebola.

But Gorsky's tenure has been colored by lawsuits and product recalls.

Along with litigation over its Baby Powder and painkillers, J&J in 2019 paid over $100 million to settle claims from states that it misrepresented the safety and effectiveness of its transvaginal surgical mesh devices.

The drugmaker recently recalled certain spray sunscreen products after discovering some of them contained low levels of benzene, a carcinogen.

J&J also faced major setbacks in its COVID-19 vaccine rollout earlier this year, when quality problems at a Baltimore manufacturing facility wasted millions of doses and delayed its production.

J&J says veteran Duato to replace Gorsky as chief executive

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Terry Dude
Terry Dude Aug 19, 2021 6:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
running for the hills Gorsky?
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email